| Year |
Citation |
Score |
| 2017 |
Caro L, de Hoon J, Depré M, Cilissen C, Miller J, Gao W, Panebianco D, Guo Z, Troemel SL, Anderson MS, Uemura N, Butterton J, Wagner J, Wright DH. Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men. Clinical and Translational Science. PMID 28796416 DOI: 10.1111/cts.12482 |
0.331 |
|
| 2012 |
Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, Butterton J. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology (Baltimore, Md.). 56: 1622-30. PMID 22576324 DOI: 10.1002/hep.25831 |
0.347 |
|
| 2012 |
Forman M, Tseng J, Palcza J, Leempoels J, Ramael S, Krishna G, Ma L, Wagner J, Troyer M. The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF A Peptides in Healthy Subjects: Results from a Rising Single Dose Study (PL02.004) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.Pl02.004 |
0.326 |
|
| 2012 |
Min K, Forman M, Dockendorf M, Palcza J, Soni P, Ma L, Krishna G, Hodsman P, Masuo K, Tanen M, Wagner J, Troyer M. A study to evaluate the pharmacokinetics and pharmacodynamics of single and multiple oral doses of the novel BACE inhibitor MK-8931 in Japanese subjects Alzheimers & Dementia. 8: 186. DOI: 10.1016/J.Jalz.2012.05.504 |
0.328 |
|
| 2012 |
Tseng J, Dockendorf M, Krishna G, Ma L, Palcza J, Leempoels J, Ramael S, Han D, Jhee S, Ereshefsky L, Wagner J, Troyer M, Forman M. Safety and pharmacokinetics of the novel BACE inhibitor MK-8931 in healthy subjects following single- and Multiple-Dose administration Alzheimers & Dementia. 8. DOI: 10.1016/J.Jalz.2012.05.500 |
0.326 |
|
| 2010 |
Luo W, Crumley T, Ebel D, Atiee GJ, Royalty J, Johnson‐Levonas AO, Wagner J, Lai E. Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers The Journal of Clinical Pharmacology. 50: 1273-1279. PMID 20107202 DOI: 10.1177/0091270009360042 |
0.31 |
|
| 2010 |
Radziszewski W, Lai E, Lazarus Shipitofsky N, Stroh M, Dishy V, Han L, Lewis W, Johnson-Levonas AO, Lutz R, Wagner J. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers. American Journal of Therapeutics. 17: 8-16. PMID 20027105 DOI: 10.1097/MJT.0b013e3181c3cbdb |
0.34 |
|
| 2009 |
Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clinical Pharmacology and Therapeutics. 86: 175-82. PMID 19421185 DOI: 10.1038/clpt.2009.60 |
0.325 |
|
| 2009 |
Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, Carlini EJ, Young S, Rushmore T, Wagner F, Lunde NM, Bieberdorf F, Greenberg H, Stone JA, Wagner JA, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clinical Pharmacology and Therapeutics. 85: 623-7. PMID 19279563 DOI: 10.1038/Clpt.2009.12 |
0.314 |
|
| 2009 |
Brainard D, Wright D, Sneddon K, Cummings C, Sun P, Valentine J, Anderson M, Warrington S, Sanderson B, Chodakewitz J, Wagner J. 937 SAFETY, TOLERABILITY, AND PHARMACOKINETICS AFTER SINGLE AND MULTIPLE DOSES OF MK-3281 IN HEALTHY SUBJECTS Journal of Hepatology. 50: S341. DOI: 10.1016/S0168-8278(09)60939-9 |
0.308 |
|
| 2008 |
Addy C, Rothenberg P, Li S, Majumdar A, Agrawal N, Li H, Zhong L, Yuan J, Maes A, Dunbar S, Cote J, Rosko K, Van Dyck K, De Lepeleire I, de Hoon J, ... ... Wagner J, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. Journal of Clinical Pharmacology. 48: 734-44. PMID 18508950 DOI: 10.1177/0091270008317591 |
0.336 |
|
| 2008 |
Boot JD, Haas SLD, Gerven JMAV, Smet MD, Leathem T, Wagner J, Denker A, Miller D, Doorn MBAV, Schoemaker RC, Cohen AF, Diamant Z. MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulmonary Pharmacology & Therapeutics. 21: 573-577. PMID 18321743 DOI: 10.1016/J.Pupt.2008.01.009 |
0.346 |
|
| 2008 |
Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, ... ... Wagner J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. Journal of Clinical Pharmacology. 48: 418-27. PMID 18258750 DOI: 10.1177/0091270008314467 |
0.345 |
|
| 2008 |
Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Merschman SA, Strohmaier KM, Ramael S, Lasseter KC, Stone JA, Gottesdiener KM, Wagner JA. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects Clinical Pharmacology and Therapeutics. 83: 293-299. PMID 17713476 DOI: 10.1038/Sj.Clpt.6100281 |
0.34 |
|
| 2007 |
Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J, Krishna R. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharmaceutics & Drug Disposition. 28: 315-22. PMID 17575559 DOI: 10.1002/bdd.560 |
0.349 |
|
| 2007 |
Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 30: 1862-4. PMID 17468348 DOI: 10.2337/dc06-2545 |
0.303 |
|
| 2007 |
Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, Wang A, Zeng W, Chen L, Wagner J, Herman G. Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects The Journal of Clinical Pharmacology. 47: 165-174. PMID 17244767 DOI: 10.1177/0091270006296523 |
0.352 |
|
| 2006 |
WRIGHT D, MAES A, YI B, BERGMAN A, LIU Q, LASSETER K, GOTTESDIENER K, WAGNER J, HERMAN G. PIII-64Multiple dose administration of MK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV, does not meaningfully alter the plasma pharmacokinetics or pharmacodynamics of single doses of warfarin Clinical Pharmacology & Therapeutics. 79: P76-P76. DOI: 10.1016/j.clpt.2005.12.272 |
0.322 |
|
| 2006 |
Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Pierre M, Wang A, Zeng W, Chen L, Wagner J. PIII-17Effect of a single cyclosporine a (NEORAL™) dose on the single-dose pharmacokinetics (PK) of sitagliptin (MK-0431), a dipeptidyl peptidase-IV inhibitor (DPP-IV), in healthy male subjects Clinical Pharmacology & Therapeutics. 79. DOI: 10.1016/J.Clpt.2005.12.225 |
0.328 |
|
| 2003 |
Dallob A, Hawkey CJ, Greenberg H, Wight N, Schepper PD, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. The Journal of Clinical Pharmacology. 43: 573-585. DOI: 10.1177/0091270003253703 |
0.339 |
|
| 1992 |
Glowacka D, Ginty DD, Wagner JA. Synergistic effects of nerve growth factor and phorbol 12-myristate 13-acetate on rapid motility and process formation in PC12 cells: the role of laminin. Journal of Neuroscience Research. 31: 263-72. PMID 1573676 DOI: 10.1002/jnr.490310207 |
0.498 |
|
| 1992 |
Ginty DD, Fanger GR, Wagner JA, Maue RA. The activity of cAMP-dependent protein kinase is required at a posttranslational level for induction of voltage-dependent sodium channels by peptide growth factors in PC12 cells. The Journal of Cell Biology. 116: 1465-73. PMID 1311713 DOI: 10.1083/Jcb.116.6.1465 |
0.481 |
|
| 1991 |
Scheibe RJ, Ginty DD, Wagner JA. Retinoic acid stimulates the differentiation of PC12 cells that are deficient in cAMP-dependent protein kinase. The Journal of Cell Biology. 113: 1173-82. PMID 1645738 DOI: 10.1083/Jcb.113.5.1173 |
0.49 |
|
| Show low-probability matches. |